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Abstract
Background: Deficiency of mitochondrial sirtuin 3 (SIRT3), a NAD+-dependent protein deacetylase that maintains
redox status and lipid homeostasis, contributes to hepatic steatosis. In this study, we investigated additional
mechanisms that might play a role in aggravating hepatic steatosis in Sirt3-deficient mice fed a high-fat diet (HFD).
Methods: Studies were conducted in wild-type (WT) and Sirt3−/− mice fed a standard diet or a HFD and in SIRT3-
knockdown human Huh-7 hepatoma cells.
Results: Sirt3−/− mice fed a HFD presented exacerbated hepatic steatosis that was accompanied by decreased
expression and DNA-binding activity of peroxisome proliferator-activated receptor (PPAR) α and of several of its
target genes involved in fatty acid oxidation, compared to WT mice fed the HFD. Interestingly, Sirt3 deficiency in
liver and its knockdown in Huh-7 cells resulted in upregulation of the nuclear levels of LIPIN1, a PPARα co-activator,
and of the protein that controls its levels and localization, hypoxia-inducible factor 1α (HIF-1α). These changes were
prevented by lipid exposure through a mechanism that might involve a decrease in succinate levels. Finally, Sirt3−/−
mice fed the HFD showed increased levels of some proteins involved in lipid uptake, such as CD36 and the VLDL
receptor. The upregulation in CD36 was confirmed in Huh-7 cells treated with a SIRT3 inhibitor or transfected with
SIRT3 siRNA and incubated with palmitate, an effect that was prevented by the Nrf2 inhibitor ML385.
Conclusion: These findings demonstrate new mechanisms by which Sirt3 deficiency contributes to hepatic steatosis.
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Background
Mitochondrial sirtuin 3 (SIRT3) is a NAD+-dependent pro-
tein deacetylase that maintains cellular homeostasis [1]. By
deacetylating lysine residues, SIRT3 regulates the activity of
many proteins to modulate mitochondrial biogenesis, en-
ergy generation and reactive oxygen species (ROS) homeo-
stasis [2]. Thus, previous studies have reported that SIRT3
controls mitochondrial ATP production through its effects
on the respiratory chain [1]. Likewise, SIRT3 protects mito-
chondrial function by modulating ROS generation through
several substrates, including superoxide dismutase 2
(SOD2), and the transcription factor Forkhead Box O3A
(FOXO3A) [3, 4]. In the liver, SIRT3 acts as a sentinel of
redox status, epigenetics, and lipid homeostasis [5]. In
addition, mice lacking Sirt3 fed a high-fat diet (HFD) show
enhanced hepatic steatosis compared to wild-type (WT)
mice [6], a finding consistent with the hyperacetylation and
reduced activity of enzymes involved in mitochondrial fatty
acid oxidation [6, 7]. However, it is currently unknown
whether Sirt3 prevents hepatic steatosis in mice fed the
HFD through additional mechanisms.
Hepatic steatosis is the early stage of non-alcoholic
fatty liver disease (NAFLD), the most common liver dis-
order and one that has reached epidemic proportions
worldwide [8]. It can progress to a more severe condi-
tion known as non-alcoholic steatohepatitis (NASH), the
necroinflammatory form of NAFLD. Several independ-
ent factors can stimulate hepatic steatosis, including
enhanced de novo lipogenesis, decreased fatty acid oxi-
dation, increased lipolysis, excessive dietary fat con-
sumption, increased fatty acid uptake and changes in the
secretion and delivery of lipoprotein particles [9–11].
The fatty acid transporter CD36 (also known as fatty
acid translocase) is an important mediator of hepatic
fatty acid uptake [12]. In humans, CD36 expression cor-
relates with triglyceride accumulation in NAFLD [13] and
shows a notable increase in the liver of animal models of
obesity and type 2 diabetes mellitus [14]. Accordingly, the
forced expression of hepatic Cd36 was accompanied by a
marked increase in hepatic fatty acid uptake and triglycer-
ide accumulation [15]. Recently, the very low-density lipo-
protein receptor (VLDLR) has also been implicated in the
development of hepatic steatosis [16]. This receptor binds
apolipoprotein E (apoE) triglyceride-rich lipoproteins such
as chylomicrons and VLDL, and intermediate density lipo-
proteins, thereby causing lipids to enter the cell [17–20].
Given the important role played by CD36 and VLDLR in
triglyceride accumulation, identifying the mechanisms that
regulate their levels may provide more clues as to how
NAFLD develops and progresses.
In this study, we show that Sirt3 deficiency aggravates
HFD-induced hepatic steatosis through a new mechanism
that prevents the adaptive increase in the hepatic levels of
proteins involved in fatty acid oxidation observed in WT
mice fed the HFD, such as LIPIN1. Moreover, Sirt3−/−
mice fed the HFD present increased hepatic levels of pro-
teins involved in lipid uptake through activation of the
oxidative stress-induced nuclear factor (erythroid-derived
2)-like 2 (Nrf2). Overall, these findings confirm SIRT3 as a
key regulator of NAFLD and shed light on new mecha-
nisms by which the decrease in the levels of this protein
may aggravate this disease.
Methods
Reagents
Control and Sirt3 siRNA were purchased from Santa Cruz
(Dallas, TX). Triglyceride levels were measured using a
commercial kit (ref. 1,001,311, SpinReact SA, St. Esteve de
Bas, Spain). ML385 (ref. SML1833) and palmitic acid (ref.
P5585) were from Sigma (St. Louis, MO) and Albumin,
Bovine Serum, fraction V, Fatty Acid-Free (ref. 126,575)
was from Merck Millipore (Burlington, MA).
Mice
Male Sirt3 knockout mice (B6; 129S5-SIRT3Gt(neo)218Lex)
that had been backcrossed into the C57BL/6JOla Hsd line
(Harlan Laboratories, Barcelona, Spain) for six generations
were obtained from the Mutant Mouse Regional Resource
Center (MMRRC). All protocols were approved by Univer-
sity of Barcelona’s Animal Care and Bioethics Committee, in
accordance with Law 5/1995, of 21 June passed by Catalan
Government, and complied with the EU Directive 2010/63/
EU for animal experiments. Male Sirt3 knockout (Sirt3−/−)
mice (8–10weeks old) and their wild-type (WT) littermates
(Sirt3+/+) were randomly distributed into two experimental
groups (n = 6) and fed either standard chow or a HFD (45%
fat, mainly from hydrogenated coconut oil, product
D08061110, Research Diets Inc., New Brunswick, NJ) for 6
weeks. All animals were killed under anesthetic conditions,
and livers were snap-frozen in liquid nitrogen immediately
after resection, then stored at − 80 °C.
Cell culture
Human Huh-7 hepatoma cells (kindly donated by Dr.
Mayka Sanchez from the Josep Carreras Leukemia Re-
search Institute) were cultured in DMEM supplemented
with 10% fetal bovine serum and 1% penicillin-
streptomycin, at 37 °C/5% CO2. Lipid-containing media
were prepared by conjugation of palmitic acid with fatty
acid-free bovine serum albumin, as previously described
[21]. siRNA transfections were performed with Lipofec-
tamine 2000 (Life Technologies, Waltham, MA). When
indicated, cells were treated with 20 μM of the HIF-1 in-
hibitor PX478 or 0.5 mM of the cell permeable succinate
donor dimethyl fumarate (DMF).
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RNA preparation and quantitative RT-PCR
The relative levels of specific mRNAs were assessed by
real-time RT-PCR, as previously described [22]. Primer se-
quences used for real-time RT-PCR as shown in Table S1.
Immunoblotting
Isolation of total and nuclear extracts was performed as de-
scribed elsewhere [21]. Proteins (30 μg) were separated by
SDS-PAGE on 10% (w/v) acrylamide separation gels and
transferred to Immobilon polyvinylidene difluoride mem-
branes (Merck Millipore). Western blot analysis was per-
formed using antibodies against HIF1α (sc-10,790), LIPIN1
(sc-98,450), Histone H3 (sc-10,809), SREBP1 (sc-365,513),
Nrf2 (sc-722), NQO1 (sc-393,736), PPARγ (sc-7273) (Santa
Cruz Biotechnology), SIRT3 (#5490), phospho-mTOR
Ser2481 (#2974), mTOR (#2972), Keap1 (#4678 s) (Cell Sig-
naling Technology Inc., Danvers, MA), GAPDH (MAB374)
(Merck Millipore), CD36 (NB400–144) (Novus Biologicals,
Centennial, CO), VLDLR (AF2258) (R&D Systems, Minne-
apolis, MN). Detection was performed with the Western
Lightning™® Plus-ECL chemiluminescence kit (PerkinElmer,
Waltham, MA, USA). The size of detected proteins was es-
timated using protein molecular-mass standards (Bio-Rad,
Hercules, CA).
Reactive oxygen species
The content of reactive oxygen species (ROS) was deter-
mined using the Oxiselect™ assay kit (Cell Biolabs Inc.,
San Diego, CA).
Succinate levels
Succinate levels were determined using the succinate
colorimetric assay kit MAK184 (Sigma). Briefly, 10 mg of
liver were homogenized with 100 μL of ice-cold succin-
ate assay buffer and then centrifuged at 10,000 g for 5
min to remove insoluble material. Supernatant was col-
lected and filtered with a 10 kDa spin filter. After adding
reaction mix, samples were incubated for 30 min at
37 °C according to manufacturer’s instructions and ab-
sorbance was measured at 450 nm.
Fatty acid uptake assay
Stock solutions of boron-dipyrromethene (BODIPY)-
C16 (Invitrogen Life Sciences, Carlsbad, CA) were pre-
pared in DMSO. After treatment with palmitate and/or
AAPBO, cells were incubated for 30 min in PBS supple-
mented with BODIPY-C16 to a final concentration of
100 nM, rinsed with ice-cold PBS and collected in the
same buffer. The fluorescence was measured in fresh
cells with a microplate fluorescence reader (excitation
490 nm and emission 510 nm).
Electrophoretic mobility shift assay
The electrophoretic mobility shift assay (EMSA) was
performed using double-stranded oligonucleotide for the
consensus binding site of the peroxisome proliferator
response element (PPRE) (Santa Cruz Biotechnology).
Nuclear extracts (NE) were isolated and EMSA was per-
formed as previously reported [21].
Hematoxylin-eosin staining
We performed hematoxylin-eosin staining as previously
reported [21].
Analysis of intracellular triglyceride content
Total lipids of liver homogenates and cultured cells were
extracted according to Bligh and Dyer [22], evaporated,
and redissolved in ethanol and triglycerides were deter-
mined using a colorimetric kit (Spinreact). Triglycerides
were normalized against the total cellular protein con-
tent of liver homogenates determined by the Bradford
protein assay. In cultured cells, culture media was re-
moved carefully after exposure to different treatments
and cells were gently washed with cold PBS, lysed in
radioimmunoprecipitation assay (RIPA) buffer and sub-
jected to homogenization. The homogenate was then
centrifuged at 15,500 g for 15 min at 4 °C to remove the
insoluble materials, after which the intracellular levels of
triglycerides were measured using a colorimetric kit
(Spinreact) and normalized with the cellular content of
protein determined by the Bradford protein assay.
Statistical analyses
Results are expressed as means ± S.D. Significant differ-
ences were established by two-way ANOVA using the
GraphPad Prism program (GraphPad Software V5.01)
(GraphPad Software Inc., San Diego, CA). When significant
variations were found by two-way ANOVA, the Tukey-
Kramer multiple comparison post-test was performed. Dif-
ferences were considered significant at p < 0.05.
Results
Feeding Sirt3−/− mice a HFD exacerbates hepatic steatosis
and attenuates the adaptive response involving PPARα
Feeding WT mice the HFD led to hepatic steatosis, as
demonstrated by hematoxylin-eosin staining (Fig. 1a)
and hepatic triglyceride quantification (Fig. 1b). In line
with previous studies [6], HFD-induced hepatic steatosis
was aggravated in Sirt3−/− mice (Figs. 1a-b). Consistent
with this finding, the mRNA levels of fibroblast growth
factor 21 (Fgf21), which reflects liver fat accumulation
[23], were higher in Sirt3−/− mice than in WT when fed
the HFD (Fig. 1c).
Dysregulation of fatty acid metabolism in liver provokes
hepatic steatosis. Hepatic fatty acids are oxidized to meet
energy needs or esterified to synthesize triglycerides, which
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are either stored within liver parenchymal cells or incorpo-
rated into VLDL particles for subsequent secretion. One of
the master regulators of fatty acid oxidation in liver is per-
oxisome proliferator-activated receptor (PPAR)α [24]. WT
mice exposed to the HFD exhibited an increased expression
of Pparα and several of its target genes involved in fatty
acid oxidation, such as acyl-CoA oxidase (Acox), medium-
chain acyl-CoA dehydrogenase (Mcad), and carnitine
palmitoyltransferase 1α (Cpt-1α), whereas this adaptive re-
sponse was partially prevented in the liver of Sirt3−/− mice
fed the HFD (Fig. 2a). In line with these changes, the DNA-
binding activity of PPARα assessed by EMSA showed an in-
crease in the nuclear extracts of livers from WT mice fed
the HFD, but this increase was blunted in Sirt3−/− mice
(Fig. 2b). The decrease in band I observed in a competition
assay with an excess of unlabelled probe demonstrated that
this complex was specific. Likewise, the decrease in the
complex observed by incubating nuclear extracts with an
antibody directed against PPARα indicated that band I con-
tained PPARα, and this decrease was specific for this nu-
clear receptor since it was not observed when samples were
incubated with an unrelated antibody (Organic Cation
Transporter 1, Oct1),
Lipid exposure abolishes the increase in hepatic LIPIN 1
and HIF-1α caused by Sirt3 deficiency: a role for succinate
Next, we focused on LIPIN 1, since this protein controls
whether fatty acids are incorporated into triglycerides or
undergo fatty acid oxidation [25]. Thus, in the cytoplasm,
LIPIN 1 promotes triglyceride accumulation and phospho-
lipid synthesis by functioning as an Mg2+-dependent phos-
phatidate phosphatase. By contrast, LIPIN 1 in the nucleus
acts as a transcriptional co-activator linked to fatty acid oxi-
dation by upregulating PPARα activity, thereby ultimately
increasing the expression of its target genes, including
Mcad and Cpt-1α [25]. Previous studies have reported that
hypoxia-inducible factor (HIF)-1α regulates LIPIN 1 levels
and localization [26, 27]. Moreover, SIRT3 loss represses
prolyl hydroxylase domain enzymes, thus leading to in-
creased levels of HIF-1α [28, 29]. Accordingly, Sirt3−/− mice
fed a standard diet presented enhanced nuclear levels of
HIF-1α and LIPIN 1, but this was reversed after they were
fed the HFD (Fig. 3a). To confirm the effects of Sirt3 defi-
ciency, human Huh7 hepatoma cells were transfected with
siRNA against SIRT3 in the presence or absence of the sat-
urated fatty acid palmitate. The decline in SIRT3 protein
levels caused by siRNA transfection targeting this gene
Fig. 1 Increased hepatic steatosis in Sirt3-deficient mice fed a HFD. a, Hematoxylin-eosin staining of livers from male wild-type (WT) and Sirt3−/−
mice fed either a standard chow or the HFD were used (n = 6 per group). Scale bar: 20 μm. b, liver triglyceride levels. c, hepatic Fgf21 expression.
a, p < 0.05 vs. WT mice fed a standard chow. b, p < 0.05 vs. WT mice fed the HFD. c, p < 0.05 vs. Sirt3−/− mice fed a standard chow
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compared to cells transfected with siRNA control (Supple-
mentary Figure 1A and B) was accompanied by increased
HIF-1α and LIPIN 1 nuclear protein levels, whereas these
changes were prevented in cells incubated with palmitate
(Fig. 3b). Moreover, palmitate exposure significantly in-
creased the expression of CPT-1α, but this fatty acid-
induced increase was blunted in cells transfected with
siRNA against SIRT3 (Fig. 3c). Overall, these findings indi-
cate that the combination of Sirt3 deficiency and the pres-
ence of lipids attenuates the increase in HIF-1α, and
therefore in LIPIN 1 levels and the expression of genes in-
volved in fatty acid oxidation, thereby eventually favoring
triglyceride accumulation. However, the question that arises
is why lipid excess prevents the increase in the levels of
HIF-1α caused by Sirt3 deficiency. Of note, succinate pro-
motes HIF-1α protein stabilization via inhibition of the HIF
hydroxylase enzymes and an excess of fatty acids has been
reported to reduce succinate, which in turn attenuates HIF-
1α levels [30]. To assess this possibility, we examined
succinate levels. Only Sirt3−/− mice fed the HFD pre-
sented a decrease in liver succinate levels (Fig. 3d).
These data suggest that the robust increase in liver
lipids observed in Sirt3−/− mice fed the HFD reduces
succinate concentrations, thereby leading to decreased
HIF-1α levels and blunting the adaptation to Sirt3 de-
ficiency. To clearly confirm the involvement of suc-
cinate and HIF-1α in the regulation of triglyceride
accumulation, Huh7 cells were exposed to the cell
permeable succinate donor DMF and the HIF-1α in-
hibitor PX478 and triglyceride levels were assessed
(Fig. 3e). Incubation of cells with palmitate led to a
significant increase in triglyceride accumulation and
this was exacerbated in cells transfected with siRNA
against SIRT3, although differences did not reach stat-
istical significance. Interestingly, the increase in trigly-
ceride levels was completely blunted when cells were
incubated with DMF, which is consistent with a role
for succinate preventing triglyceride accumulation.
However, the effect of DMF was attenuated in cells
incubated with DMF and the HIF-1α inhibitor PX478,
indicating that the activity of this transcription factor
is required to prevent triglyceride accumulation. Thus,
in vitro findings confirm that an increase in succinate
reverses triglyceride accumulation in Sirt3-deficient
cells exposed to palmitate and that this effect of suc-
cinate requires the activity of HIF-1α.
Fig. 2 Hepatic dysregulation of the expression of genes involved in fatty acid oxidation in Sirt3-deficient mice fed a HFD. a, Hepatic mRNA levels
of genes involved in fatty acid metabolism of livers from WT and Sirt3−/− mice fed either a standard chow or a HFD. Data are presented as the
mean ± S.D. (n = 6 per group). b, autoradiograph of EMSA to show PPAR-DNA binding activity was performed with a 32P-labeled PPRE nucleotide
and crude nuclear protein extract (NE) from livers of WT and Sirt3−/− mice fed either a standard chow or a HFD. a, p < 0.05 vs. WT mice fed a
standard chow. b, p < 0.05 vs. WT mice fed a HFD. c, p < 0.05 vs. Sirt3−/− mice fed a standard chow. Ab, antibody
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Increased lipogenesis is not involved in increased hepatic
steatosis in Sirt3−/− mice fed the HFD
Next, we examined whether increased lipogenesis was also
involved in the exacerbation of hepatic steatosis in Sirt3−/−
mice fed the HFD. Mammalian target of rapamycin
(mTOR) complex 1 (mTORC1) regulates sterol regulatory
element-binding protein (SREBP), the master regulator of
fatty acid biosynthetic gene expression [31], by controlling
the nuclear entry of LIPIN 1. Once in the nucleus, LIPIN
1 promotes the downregulation of nuclear SREBP1c
Fig. 3 HFD abolishes the increase in hepatic nuclear levels of HIF-1α and LIPIN1 levels observed in Sirt3-deficient mice. a, hepatic nuclear levels of
HIF-1α and LIPIN1 from WT and Sirt3−/− mice fed either a standard chow or a HFD. Data are presented as the mean ± S.D. (n = 6 per group). a,
p < 0.05 vs. WT mice fed a standard chow. b, p < 0.05 vs. WT mice fed a HFD. c, p < 0.05 vs. Sirt3−/− mice fed a standard chow. b, nuclear protein
levels of HIF-1α and LIPIN1 in Huh-7 cells transfected with control (CT) or SIRT3 siRNA and incubated with fatty acid free-BSA or BSA-palmitate
(0.3 mM) (Pal) for 24 h. c, hepatic CPT-1α mRNA levels. a, p < 0.05 vs. CT siRNA cells. b, p < 0.05 vs. CT siRNA cells incubated with palmitate. c, p <
0.05 vs. SIRT3 siRNA cells. d, succinate levels in the liver of WT and Sirt3−/− mice fed either a standard chow or a HFD. a, p < 0.05 vs. WT mice fed
a standard chow. b, p < 0.05 vs. WT mice fed a HFD. c, p < 0.05 vs. Sirt3−/− mice fed a standard chow. e, triglyceride levels in Huh-7 cells
transfected with control (CT) or SIRT3 siRNA and incubated with fatty acid free-BSA or BSA-palmitate (0.3 mM) (Pal) for 24 h in the presence or
absence of DMF and/or PX478. a, p < 0.05 vs. CT siRNA cells. b, p < 0.05 vs. CT siRNA cells incubated with palmitate. c, p < 0.05 vs. SIRT3 siRNA
cells. d, p < 0.05 vs. SIRT3 siRNA cells incubated with palmitate. e, p < 0.05 vs. SIRT3 siRNA cells incubated with palmitate and DMF
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abundance. Additionally, mTORC1 is also necessary for
activating the processing of SREBP1c to its mature form
[32]. Since it has recently been reported that a loss of
SIRT3 hyperactivates mTORC1 [33], we assessed whether
this pathway was activated in our conditions. Only Sirt3−/−
mice fed the HFD presented an increase in phospho-
mTOR, although the differences did not reach statistical
significance (Fig. 4a). When we examined the precursor
and mature forms of SREBP1, we observed no significant
increase in the mature form of this transcription factor in
Sirt3−/− mice fed a HFD compared to WT mice fed the
same diet (Fig. 4b). This would suggest that increased fatty
acid synthesis was not a key mechanism in the exacerba-
tion of steatosis in Sirt3−/− mice fed the HFD. Accord-
ingly, the expression levels of two genes involved in
lipogenesis, stearoyl-CoA desaturase 1 (Scd1) and fatty
acid synthase (Fas), did not increase significantly in the
liver of Sirt3−/− mice fed the HFD (Fig. 4c).
Fig. 4 Lipogenesis is not increased in Sirt3-deficient mice fed a HFD. a, protein levels of total and phospho-mTOR in liver from wild-type (WT)
and Sirt3−/− mice fed either a standard chow or a HFD. b, protein levels of precursor (p) and mature (m) forms of SREBP1. c, hepatic Scd1 and Fas
mRNA levels. Data are presented as the mean ± S.D. (n = 6 per group). a, p < 0.05 vs. WT mice fed a standard chow. b, p < 0.05 vs. WT mice fed a
HFD. c, p < 0.05 vs. Sirt3−/− mice fed a standard chow
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Lipid exposure in the presence of Sirt3 deficiency
upregulates the levels of proteins involved in lipid uptake
through Nrf2
We also determined whether the aggravation of hepatic
steatosis in Sirt3−/− mice fed the HFD involved changes in
the levels of proteins that favor lipid uptake. First, we
checked the VLDLR levels. The expression and protein
levels of this receptor increased significantly only in the
liver of Sirt3−/− mice fed the HFD (Fig. 5a and b). With re-
spect to CD36 protein levels, we observed a significant in-
crease in WT mice fed the HFD diet, but this increase was
exacerbated in Sirt3−/− mice fed the same diet (Fig. 5c).
Since the expression of both Vldlr [34] and Cd36 [35, 36]
is regulated by Nrf2, we examined the levels of this tran-
scription factor and its target genes. Exposure to the
HFD caused a similar increase in the nuclear protein
levels of Nrf2 in WT and Sirt3−/− mice (Fig. 5d),
whereas the levels of the Nrf2 repressor protein
Keap1 (Kelch-like ECH-associated protein 1) were
only increased in WT mice fed the HFD diet and in
Sirt3−/− mice fed the same diet (Fig. 5e). However, it
has been reported that Nrf2 shows a transient increase
[37], and assessing the expression of its target genes is a
more effective way of checking its activity. In fact, the pro-
tein levels of the Nrf2-target gene NAD(P)H:quinone oxi-
doreductase (NQO1) were only significantly higher in
Fig. 5 Enhanced hepatic VLDLR and CD36 levels in Sirt3-deficient mice fed a HFD. mRNA abundance (a) and protein levels (b) of VLDLR in livers
of WT and Sirt3−/− mice fed either a standard chow or a HFD. CD36 (c), total and phospho-Nrf2 (d), Keap1 (e) and NQO1 (f) protein levels. g, ROS
levels. h, PPARγ protein levels. Data are presented as the mean ± S.D. (n = 6 per group). a, p < 0.05 vs. WT mice fed a standard chow. b, p < 0.05 vs.
WT mice fed a HFD. c, p < 0.05 vs. Sirt3−/− mice fed a standard chow
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Sirt3−/− mice fed the HFD (Fig. 5f), thus suggesting that
the activity of Nrf2 was higher in this treatment group.
The higher activity of the redox-sensitive transcription
factor Nrf2 in the livers of Sirt3−/− mice fed the HFD was
consistent with the increased levels of ROS in this group
of animals (Fig. 5g). In addition, CD36 has been shown to
be a direct target of PPARγ [36] and the protein levels of
this PPAR isotype were reduced in the livers of Sirt3−/−
mice fed a standard diet. However, when these mice were
fed the HFD, the PPARγ levels were restored (Fig. 5h).
Exposure of Huh7 hepatoma cells to the Sirt3 inhibitor 5-
amino-2-(4-aminophenyl) benzoxazole (AAPBO, 100 μM)
[38, 39] significantly increased VLDLR mRNA levels, and
this situation was exacerbated when cells were exposed to
palmitate (Fig. 6a). Similarly, the combination of the Sirt3
inhibitor and palmitate increased the protein levels of
CD36 and NQO1 (Fig. 6b). In agreement with the changes
in CD36 protein levels, cellular fatty acid uptake deter-
mined with the BODIPY-labeled C16 fatty acid analog
showed an increase in BODIPY-C16 uptake in cells
Fig. 6 The increase in CD36 levels caused by lipids in Sirt3-deficient hepatocytes is mediated by Nrf2. VLDLR mRNA abundance (a) and protein
levels of VLDLR and NQO1, an Nrf-2-target gene, (b) were assessed in Huh-7 cells incubated with fatty acid free-BSA or BSA-palmitate (0.3 mM)
and exposed to either vehicle or the Sirt3 inhibitor AAPBO (100 μM) for 16 h. a, p < 0.05 vs. CT. b, p < 0.05 vs. CT cells incubated with palmitate. c,
p < 0.05 vs. CT cells treated with AAPBO. c, fatty acid uptake in Huh-7 cells incubated with fatty acid free-BSA or BSA-palmitate (0.3 mM) and
exposed to either vehicle or the Sirt3 inhibitor AAPBO (100 μM) for 16 h was measured by the uptake of BODIPY-C16. a, p < 0.05 vs. CT. b, p < 0.05
vs. CT cells incubated with palmitate. c, p < 0.05 vs. CT cells treated with AAPBO. mRNA abundance (d) and protein levels of VLDLR (e) in Huh-7
cells transfected with control (CT) or SIRT3 siRNA and incubated in the presence or absence 0.3 mM palmitate (Pal) for 24 h. Protein levels of CD36
(f), NQO1 (g) and PPARγ (h) in Huh-7 cells transfected with control (CT) or SIRT3 siRNA and incubated in the presence or absence 0.3 mM
palmitate (Pal) or the Nrf2 inhibitor ML385 (10 μM) for 24 h. a, p < 0.05 vs. CT siRNA cells. b, p < 0.05 vs. CT siRNA cells incubated with palmitate. c,
p < 0.05 vs. SIRT3 siRNA cells. d, p < 0.05 vs. CT siRNA cells incubated with palmitate and ML385
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exposed to palmitate and the Sirt3 inhibitor AAPBO
(Fig. 6c). In contrast to the effects of the Sirt3 inhibi-
tor, Sirt3 knockdown did not affect VLDLR mRNA or
protein levels (Fig. 6d and e), thus suggesting that the
remaining levels of SIRT3 following knockdown can
prevent the increase in VLDLR abundance. Finally,
Sirt3 knockdown in the presence of palmitate caused
a remarkable increase in CD36 protein levels that was
prevented by the Nrf2 inhibitor ML385 [40] (Fig. 6f),
thus indicating that this increase might be the result
of an increase in Nrf2 activity. Accordingly, the pro-
tein levels of NQO1 were upregulated (Fig. 6g),
whereas no changes were observed in the PPARγ pro-
tein levels (Fig. 6h).
Discussion
Previous studies have reported that Sirt3-deficient mice
show accelerated steatosis compared to WT mice be-
cause of hyperacetylation and the subsequent reduced
activity of mitochondrial metabolic enzymes such as
long-chain acyl-CoA dehydrogenase (LCAD) [6]. Here,
we present evidence that Sirt3 deficiency in the context
of an excess of lipids exacerbates hepatic steatosis
through different new mechanisms, thus affecting the
expression of transcriptional co-activators involved in
fatty acid oxidation and of genes involved in lipid up-
take. In our study, WT and Sirt3-deficient mice were fed
either a standard diet or the HFD. Under these condi-
tions, WT mice fed the HFD presented an increase in
the expression of hepatic genes involved in fatty acid
oxidation (Pparα and its target genes), probably as an
initial adaptive mechanism to overcome the higher lipid
supply. This adaptive mechanism involving PPARα and
its target genes was abrogated in the liver of Sirt3-defi-
cient mice fed the HFD. The findings of this study show
that the increase in the DNA-binding activity of PPARα
and the expression of its target genes are abolished in
the liver of Sirt3-deficient mice fed the HFD. This indi-
cates that the absence of SIRT3 accelerates fatty acid ac-
cumulation and liver hepatic steatosis. In fact, the
expression of Pparα and its target genes is upregulated
in wild-type mice fed the HFD for 6 weeks. In contrast,
the increase in the expression of Pparα and its target
genes observed in wild-type mice fed the HFD was not
observed in Sirt3-deficient mice fed the HFD, suggesting
that the deficiency of this sirtuin accelerates the accu-
mulation of lipids. Further studies are needed to clarify
what is the contribution in the decrease of the expres-
sion of these genes involved in fatty acid oxidation to
the increased hepatic triglyceride accumulation. Overall,
the findings of this study suggest that Sirt3 deficiency in
the context of an excess of lipids accelerates the accu-
mulation of lipids and the subsequent processes that
prevent the increase in the expression of genes involved
in fatty acid oxidation.
The lack of induction in PPARα in the liver of Sirt3-
deficient mice fed the HFD might involve a decrease in
the nuclear levels of LIPIN 1, a PPARα transcriptional
co-activator [25]. LIPIN 1 levels and localization are reg-
ulated by HIF-1α [26, 27], a transcription factor, which
in turn is upregulated by the loss of Sirt3 [28, 29]. The
lack of increase in nuclear LIPIN 1 in the liver of Sirt3-
deficient mice fed the HFD was accompanied by a de-
crease in HIF-1α compared to Sirt3-deficient mice fed a
standard diet. Knockdown of SIRT3 in human hepatoma
cells confirmed the upregulation in both HIF-1α and
LIPIN 1 protein levels, whereas this increase was blunted
when cells were exposed to palmitate. Therefore, Sirt3
deficiency provokes an increase in HIF-1α levels that
might trigger an adaptive mechanism, which promotes
the translocation of LIPIN 1 to the nucleus. This would
reduce its impact in the synthesis of triglycerides in the
cytoplasm and would prepare the cell to attenuate lipid
accumulation in hepatocytes through the activation of
PPARα. These findings are consistent with the protective
effect reported for HIF-1α induction in alcoholic fatty
liver [41]. This metabolic flexibility would be lost in the
presence of an excess of lipids through the reduction in
succinate levels. This metabolite inhibits HIF hydroxy-
lase enzymes and its decrease attenuates HIF-1α levels
[30]. The findings of this study also suggest that challen-
ging wild-type mice with the HFD or Sirt3-deficient
mice with a standard diet is not enough to promote a
decrease in succinate levels and that only the combin-
ation of Sirt3 deficiency with the HFD results in the re-
duction of succinate. Since an excess fatty acids has
been reported to reduce succinate, leading to a decrease
in HIF-1α levels [30], the results of this study suggest
that only the exacerbation of the accumulation of fatty
acids observed in Sirt3-deficient mice fed the HFD leads
to a decrease in hepatic succinate levels.
Additional mechanisms, including lipogenesis, may
play a role aggravating hepatic steatosis in Sirt3-deficient
mice fed the HFD compared to WT mice. Sirt3-deficient
mice fed a standard diet have previously been reported
to show an increase in the expression of one lipogenic
gene only, Scd1, whereas the expression of other lipo-
genic genes and Srebp1c was not affected [6]. The en-
hanced expression of Scd1 was attributed to the increase
in hepatic saturated fatty acids [6]. In this study we re-
port that feeding Sirt3-deficient mice the HFD also re-
sults in enhanced levels of the mature SREBP1 form,
although the increase did not reach significance. This
finding was consistent with the increase in phospho-
mTOR levels in these animals, since mTORC1 regulates
nuclear LIPIN 1 localization to control nuclear SREBP1c
abundance [26] and also regulates the processing of
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SREBP1c to its mature form [27]. The slight increase in
SREBP1c abundance did not significantly affect the ex-
pression of genes involved in lipogenesis. This process is
therefore unlikely to be involved in the increased accu-
mulation of triglycerides observed in Sirt3-deficient mice
fed the HFD.
Finally, when we evaluated the expression and protein
levels of genes involved in lipid uptake (VLDLR and
CD36), we observed that their levels increased in the
liver of Sirt3-deficient mice fed the HFD. The expression
of these two genes is regulated by the redox transcrip-
tion factor Nrf2 [34–36] and, consistent with the role of
Nrf2 in the upregulation of these genes, the protein
levels of its target gene NQO1 increased only in Sirt3-
deficient mice fed the HFD. The increase in CD36 was
confirmed in cultured human hepatoma cells, where
either SIRT3 inhibition or knockdown in the presence of
palmitate raised both CD36 and NQO1. However, the
increase in VLDLR in these cells was observed only fol-
lowing SIRT3 inhibition, whereas SIRT3 knockdown in-
creased neither VLDLR mRNA nor protein levels.
Several differences might account for this discrepancy
(e.g. human cells compared to mice and chronic HFD
compared to 24 h of palmitate incubation) but, since
VLDLR is also dependent on HIF-1α [42], the increased
VLDLR levels caused by Nrf2 might be affected differ-
ently by these two transcription factors in cultured cells
and liver. In addition, another factor that can explain
these differences is that the magnitude of the changes is
likely to depend on the degree of the decrease in SIRT3
activity, being higher with the inhibitor than with Sirt3
knockdown.
Notably, chronic HFD feeding has been reported to reduce
the hepatic levels of SIRT3 [6, 43]. Thus, we can envisage the
following potential sequence of events in mice fed the HFD
(Fig. 7). Chronic HFD feeding would reduce SIRT3 levels,
which in turn would result in hyperacetylation and a subse-
quent decrease in the activity of enzymes involved in mito-
chondrial β-oxidation, thus leading to hepatic steatosis. The
decrease in SIRT3 levels might activate an adaptive mechan-
ism through the increase in nuclear HIF-1α and LIPIN 1
levels to attenuate hepatic steatosis. However, the progressive
decrease in SIRT3 levels would exacerbate the increase in
lipid uptake, through the upregulation of CD36 and VLDLR,
respectively. Finally, the progressive accumulation of fatty
acids in the cells would reduce succinate levels, thereby
blunting the increase in HIF-1α and LIPIN1 and ultimately
aggravating steatosis. The findings of this study performed
in vitro and in vivo support the presence of a new adaptive
mechanism that may offer additional strategies to treat
NAFLD by regulating the HIF-1α-LIPIN 1 pathway that
need to be confirmed by additional studies.
Although there is yet little evidence about whether the
mechanism described in this study operates in human
NAFLD, it has been reported that a unique single nu-
cleotide polymorphism in the SIRT3 gene results in re-
duced SIRT3 enzymatic efficiency and an increased risk
of developing metabolic syndrome and hepatic steatosis
in humans [6]. It would be interesting to examine the
translational potential of the findings of this study by
conducting a study to assess whether hepatic CD36 and
VLDLR are upregulated and as to whether the increase
in succinate levels plays a role in accelerating the devel-


















Fig. 7 Potential new mechanisms by which Sirt3 deficiency promotes hepatic steatosis in mice fed a HFD. Exposure to a HFD reduces Sirt3 and
contributes to triglyceride accumulation in the liver. However, hepatic lipid accumulation is attenuated by the activation of an adaptive
mechanism involving an increase in nuclear HIF-1α and Lipin 1. Longer exposures to a HFD exacerbates Sirt3 decrease leading to higher uptake
of lipids through an Nrf-2 mediated increase in CD36 and VLDLR. This results in a higher increase in fatty acid accumulation, which in turn
reduces succinate levels, ultimately suppressing the adaptive increase in HIF-1α and Lipin 1. FAO: Fatty acid oxidation
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Conclusions
Overall, the findings of this study point to SIRT3 as a
key protein for controlling the PPARα-target genes in-
volved in fatty acid oxidation through the HIF-1α-LIPIN
1 pathway. The activation of this pathway is disturbed
by the presence of lipids that favor the exclusion of LIPI
N 1 from the nucleus, where it co-activates fatty acid
synthesis. In addition, Sirt3 deficiency promotes liver tri-
glyceride accumulation by increasing CD36 and VLDLR
levels via a Nrf2-dependent mechanism. The findings of
this study open new mechanisms that can contribute to
NAFLD and whose regulation may offer potential thera-
peutic opportunities to treat this condition.
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